{ "items": [ "\n\n
\n\n
\n\n \n\n
\n \n \n
\n \n
\n \n \n

\n Identification of a Chemical Probe for Family VIII Bromodomains through Optimization of a Fragment Hit.\n

\n \n \n

\n \n Journal article\n \n

\n \n\n \n \n \n

Gerstenberger BS. et al, (2016), J Med Chem, 59, 4800 - 4811

\n \n \n \n

\n

\n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n \n
\n \n \n

\n A poised fragment library enables rapid synthetic expansion yielding the first reported inhibitors of PHIP(2), an atypical bromodomain.\n

\n \n \n

\n \n Journal article\n \n

\n \n\n \n \n \n

Cox OB. et al, (2016), Chem Sci, 7, 2322 - 2330

\n \n \n \n

\n

\n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n \n
\n \n \n

\n Development of chemical probes for the bromodomains of BRD7 and BRD9.\n

\n \n \n

\n \n Journal article\n \n

\n \n\n \n \n \n

Clark PGK. et al, (2016), Drug Discov Today Technol, 19, 73 - 80

\n \n \n \n

\n

\n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n \n
\n \n \n

\n 8-Substituted Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives As Potent, Cell Permeable, KDM4 (JMJD2) and KDM5 (JARID1) Histone Lysine Demethylase Inhibitors.\n

\n \n \n

\n \n Journal article\n \n

\n \n\n \n \n \n

Bavetsias V. et al, (2016), J Med Chem, 59, 1388 - 1409

\n \n \n \n

\n

\n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n \n
\n \n \n

\n Discovery of a Chemical Tool Inhibitor Targeting the Bromodomains of TRIM24 and BRPF.\n

\n \n \n

\n \n Journal article\n \n

\n \n\n \n \n \n

Bennett J. et al, (2016), J Med Chem, 59, 1642 - 1647

\n \n \n \n

\n

\n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n \n
\n \n \n

\n Recent Progress in Histone Demethylase Inhibitors.\n

\n \n \n

\n \n Journal article\n \n

\n \n\n \n \n \n

McAllister TE. et al, (2016), J Med Chem, 59, 1308 - 1329

\n \n \n \n

\n

\n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n \n
\n \n \n

\n Structure-Based Identification of Inhibitory Fragments Targeting the p300/CBP-Associated Factor Bromodomain.\n

\n \n \n

\n \n Journal article\n \n

\n \n\n \n \n \n

Chaikuad A. et al, (2016), J Med Chem, 59, 1648 - 1653

\n \n \n \n

\n

\n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n \n
\n \n \n

\n Deciphering the true antiproliferative target of an MK2 activation inhibitor in glioblastoma.\n

\n \n \n

\n \n Journal article\n \n

\n \n\n \n \n \n

Brennan PE., (2016), Cell Death Dis, 7

\n \n \n \n

\n

\n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n \n
\n \n \n

\n Design and utilisation of a poised fragment library in the search for inhibitors of PHIP(2), an atypical bromodomain\n

\n \n \n

\n \n Conference paper\n \n

\n \n\n \n \n \n

Cox O. et al, (2016), ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 251

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n \n
\n \n \n

\n Enantioselective synthesis of a chemical probe for KDM2a\n

\n \n \n

\n \n Conference paper\n \n

\n \n\n \n \n \n

Gerken P. et al, (2016), ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 252

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n \n
\n \n \n

\n PRECLINICAL EFFICACY OF ALK2 INHIBITORS IN ACVR1 MUTANT DIPG\n

\n \n \n

\n \n Other\n \n

\n \n\n \n \n \n

Carvalho D. et al, (2016), NEURO-ONCOLOGY, 18, 154 - 154

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n \n
\n \n \n

\n PRECLINICAL EFFICACY OF ALK2 INHIBITORS IN ACVR1 MUTANT DIPG\n

\n \n \n

\n \n Other\n \n

\n \n\n \n \n \n

Carvalho D. et al, (2016), NEURO-ONCOLOGY, 18, 63 - 63

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n \n
\n \n \n

\n Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy.\n

\n \n \n

\n \n Journal article\n \n

\n \n\n \n \n \n

Picaud S. et al, (2015), Cancer Res, 75, 5106 - 5119

\n \n \n \n

\n

\n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n \n
\n \n \n

\n Corrigendum: The promise and peril of chemical probes.\n

\n \n \n

\n \n Journal article\n \n

\n \n\n \n \n \n

Arrowsmith CH. et al, (2015), Nat Chem Biol, 11

\n \n \n \n

\n

\n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n \n
\n \n \n

\n Selective targeting of the BRG/PB1 bromodomains impairs embryonic and trophoblast stem cell maintenance.\n

\n \n \n

\n \n Journal article\n \n

\n \n\n \n \n \n

Fedorov O. et al, (2015), Sci Adv, 1

\n \n \n \n

\n

\n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n \n
\n \n \n

\n Betti reaction enables efficient synthesis of 8-hydroxyquinoline inhibitors of 2-oxoglutarate oxygenases.\n

\n \n \n

\n \n Journal article\n \n

\n \n\n \n \n \n

Thinnes CC. et al, (2015), Chem Commun (Camb), 51, 15458 - 15461

\n \n \n \n

\n

\n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n \n
\n \n \n

\n Inflammatory Signaling by NOD-RIPK2 Is Inhibited by Clinically Relevant Type II Kinase Inhibitors.\n

\n \n \n

\n \n Journal article\n \n

\n \n\n \n \n \n

Canning P. et al, (2015), Chem Biol, 22, 1174 - 1184

\n \n \n \n

\n

\n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n \n
\n \n \n

\n CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses.\n

\n \n \n

\n \n Journal article\n \n

\n \n\n \n \n \n

Hammitzsch A. et al, (2015), Proc Natl Acad Sci U S A, 112, 10768 - 10773

\n \n \n \n

\n

\n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n \n
\n \n \n

\n The promise and peril of chemical probes.\n

\n \n \n

\n \n Journal article\n \n

\n \n\n \n \n \n

Arrowsmith CH. et al, (2015), Nat Chem Biol, 11, 536 - 541

\n \n \n \n

\n

\n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n \n
\n \n \n

\n Design and synthesis of potent and selective inhibitors of BRD7 and BRD9 bromodomains\n

\n \n \n

\n \n Journal article\n \n

\n \n\n \n \n \n

Hay DA. et al, (2015), MedChemComm, 6, 1381 - 1386

\n \n \n \n

\n

\n

\n \n \n
\n\n
\n\n
\n\n\n" ], "more": "\n\n \n \n Load More\n \n \n\n", "msg": "" }